Practical Evidence-Based Recommendations for Patients with Multiple Sclerosis Who Want to Have Children

Neurology and Therapy
Yara D FragosoClaudia Cristina Ferreira Vasconcelos

Abstract

Multiple sclerosis (MS) management presently aims to reach a state of no (or minimal) evidence of disease activity. The development and commercialization of new drugs has led to a renewed interest in family planning, since patients with MS may face a future with reduced (or no) disease-related neurological disability. The advice of neurologists is often sought by patients who want to have children and need to know more about disease control at conception and during pregnancy and the puerperium. When MS is well controlled, the simple withdrawal of drugs for patients who intend to conceive is not an option. On the other hand, not all treatments presently recommended for MS are considered safe during conception, pregnancy and/or breastfeeding. The objective of the present study was to summarize the practical and evidence-based recommendations for family planning when our patients (women and men) have MS.Funding TEVA Pharmaceutical Brazil.

References

Mar 1, 1995·Obstetrics and Gynecology·S Leader, P J Perales
Jun 1, 1994·Journal of the American Academy of Dermatology·P J AltmeyerG Lutz
Jun 1, 1993·Antimicrobial Agents and Chemotherapy·A WaysbortJ Puel
Jul 1, 1996·Multiple Sclerosis : Clinical and Laboratory Research·T MoreauA Compston
Jun 5, 1999·Reviews of Reproduction·F SajiM Koyama
Dec 12, 2001·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·T ZiemssenR Hohlfeld
Mar 21, 2002·American Journal of Obstetrics and Gynecology·Beth A MuellerCathy W Critchlow
Jun 14, 2003·The Cochrane Database of Systematic Reviews·C TausA Solari
Aug 21, 2003·Multiple Sclerosis : Clinical and Laboratory Research·C PolmanUNKNOWN European Oral Interferon Beta-1a in Relapsing-Remitting MS Study Group
Apr 6, 2004·Leukemia & Lymphoma·Robert Z Orlowski
Jun 30, 2004·European Journal of Obstetrics, Gynecology, and Reproductive Biology·Simone FerreroNicola Ragni
Jul 9, 2004·Journal of the Neurological Sciences·Suhali Al-ShammriRaj Raghupathy
Oct 9, 2004·Multiple Sclerosis : Clinical and Laboratory Research·J de SezeP Vermersch
Dec 2, 2004·Expert Opinion on Emerging Drugs·Clyde Markowitz
Apr 28, 2005·Expert Review of Neurotherapeutics·Richard A Rudick, Alfred Sandrock
Jun 19, 2007·Neurology·Clyde E Markowitz
Jul 12, 2007·The Neurologist·Kenneth P Johnson
Sep 6, 2007·The Annals of Pharmacotherapy·Brandon A BrownLisa M McDevitt
Feb 15, 2008·The New England Journal of Medicine·Stephen L HauserUNKNOWN HERMES Trial Group
Feb 27, 2009·Congenital Anomalies·Ryou FukushimaHiroshi Kitagawa
Mar 26, 2009·Multiple Sclerosis : Clinical and Laboratory Research·Y H ChenH C Lin
May 21, 2009·Expert Opinion on Emerging Drugs·Jung Seok KangKang Choon Lee
Jun 10, 2009·Archives of Neurology·Annette Langer-GouldLorene M Nelson
Jun 23, 2009·Journal of the Neurological Sciences·Stefan M Gold, Rhonda R Voskuhl
Jul 25, 2009·Birth Defects Research. Part B, Developmental and Reproductive Toxicology·Nele Pentsuk, Jan Willem van der Laan
Aug 21, 2009·Multiple Sclerosis : Clinical and Laboratory Research·C Weber-Schoendorfer, C Schaefer
Aug 25, 2009·Obstetrics and Gynecology·Maureen CroninJürgen Dinger
Nov 19, 2009·Journal of Neurology·Hans-Peter HartungGiancarlo Comi Giancarlo Comi
Nov 26, 2009·Journal of Neurology·Kerstin HellwigRalf Gold
Dec 22, 2009·Central Nervous System Agents in Medicinal Chemistry·Masaaki NiinoHidenao Sasaki
Jan 12, 2010·Clinical Neuropharmacology·Jerold Chun, Hans-Peter Hartung
Feb 24, 2010·Acta Neurologica Scandinavica·Krystyna Mitosek-SzewczykE Belniak
May 4, 2010·Movement Disorders : Official Journal of the Movement Disorder Society·Sarah M KranickLawrence I Golbe
Oct 13, 2010·Toxicological Sciences : an Official Journal of the Society of Toxicology·Anu VaidyanathanJoseph C Beyer
Oct 29, 2010·Expert Review of Clinical Immunology·Hatem A AzimFedro A Peccatori
Nov 3, 2010·The Australian and New Zealand Journal of Psychiatry·Adaobi UdechukuKlara Szego
Nov 10, 2010·Archives of Neurology·Annette Langer-GouldLorene M Nelson
Nov 17, 2010·Neurology·M P AmatoUNKNOWN MS Study Group of the Italian Neurological Society
Nov 26, 2010·Blood·Eliza F ChakravartyPamela Farmer

❮ Previous
Next ❯

Citations

Mar 24, 2020·Therapeutic Advances in Neurological Disorders·Kerstin HellwigAlessandra Adamo
Apr 3, 2021·Multiple Sclerosis Journal - Experimental, Translational and Clinical·Lubna AlmouzainFiona Hamilton
Apr 17, 2021·Revista brasileira de ginecologia e obstetrícia : revista da Federação Brasileira das Sociedades de Ginecologia e Obstetrícia·Gabrielle Maria Carvalho de BarrosSabina Bastos Maia
Aug 6, 2021·Multiple Sclerosis Journal - Experimental, Translational and Clinical·Dessa SadovnickPenelope Smyth
Aug 20, 2021·Multiple Sclerosis : Clinical and Laboratory Research·Hélène TillautEmmanuelle Leray

❮ Previous
Next ❯

Methods Mentioned

BETA
cesarean section

Software Mentioned

SciELO
Google Scholar

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.